This activity is expired and is no longer available for CME credit.


Transforming Treatment Regimens to Improve the Management of Diabetic Retinopathy and Neovascular Age-related Macular Degeneration

Author(s)/Faculty: Andrew A. Moshfeghi, MD, MBA; Jorge A. Fortun, MD
Release Date: 12/18/2020Expiration Date: 12/17/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: VideoProvider:
The incorporation of anti-vascular endothelial growth factor (VEGF) therapies into management protocols for patients with neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) have greatly enhanced visual outcomes. In patients with nAMD, significant visual acuity gains have been demonstrated, yet suboptimal outcomes have also been observed due to lack of patient adherence associated with treatment burden. In DR, early intervention with anti-VEGF therapies has demonstrated significant slowing of disease progression and reduction in vision threatening complications. Dosing strategies aimed at extending the time between dosing intervals while maintaining early visual acuity gains are evolving. In this CME activity, experts in the field will evaluate injection protocols that have been shown to improve the long-term management of DR and nAMD, as well as discuss how the persistence of retinal fluid post-treatment may influence visual outcomes in patients with retinal diseases.